Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
NCT03225716 · Dana-Farber Cancer Institute · PHASE1 · terminated · last registry update 2024-05-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision to end follow-up early” | – | Registry record, Dana-Farber Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CXCR4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-21Results posted on the registry: BioLineRx, Ltd., 1.25 mg/kg BL-8040 + BL-8040-matching placebo + 2 mg/kg BL-8040 (NCT05293171)
- 2025-01-07Results posted on the registry: Fred Hutchinson Cancer Center, Anti-Thymocyte Globulin + Cyclophosphamide (NCT01413100)
- 2024-11-06Also stopped (terminated): Ensoma, MGTA-145 + Plerixafor (NCT04762875)
- 2024-10-30Results posted on the registry: X4 Pharmaceuticals, X4P-001 (NCT03005327)
- 2024-10-08Results posted on the registry: Genetix Biotherapeutics Inc., lovo-cel (NCT02140554)
- 2024-09-05Results posted on the registry: BioLineRx, Ltd., BL-8040 + Atezolizumab (NCT03154827)
- 2024-09-05Also stopped (terminated): BioLineRx, Ltd., BL-8040 + Atezolizumab (NCT03154827)
- 2024-08-29Results posted on the registry: Ensoma, MGTA-145 + Plerixafor (NCT04762875)
- 2024-08-14Results posted on the registry: X4 Pharmaceuticals, X4P-001 + axitinib (NCT02667886)
- 2024-07-23Phase 3 first posted: Guangzhou Gloria Biosciences Co., Ltd., Motixafortide+G-CSF + Placebo+G-CSF (NCT06514508)
- 2024-06-26Results posted on the registry: Lawrence D Recht, Plerixafor + Temozolomide (NCT03746080)
- 2024-05-17Also stopped (terminated): Fred Hutchinson Cancer Center, Filgrastim + Genetically Engineered Hematopoietic Stem Progenitor Cells (NCT01331018)
- 2024-04-12Also stopped (terminated): Children's Hospital Medical Center, Cincinnati, ARU-1801 (NCT02186418)
- 2024-02-20Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cemiplimab + Plerixafor (NCT04177810)
- 2023-11-01Also stopped (terminated): Jonsson Comprehensive Cancer Center, Aldesleukin + Busulfan (NCT03240861)
- 2023-11-01Results posted on the registry: Spexis AG, Eribulin + Balixafortide (NCT03786094)
- 2023-11-01Also stopped (terminated): Spexis AG, Eribulin + Balixafortide (NCT03786094)
- 2023-09-28Phase 3 first posted: X4 Pharmaceuticals, Mavorixafor + Placebo (NCT06056297)
- 2023-09-14Results posted on the registry: Center for International Blood and Marrow Transplant Research, Plerixafor (NCT01696461)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision